Hepatitis C

No single biomarker or multimarker score significantly reached the predefined acceptability thresholds for patients with NASH and clinically significant fibrosis.

Liver stiffness, body weight, and metabolic risk factors were significantly and comparably reduced in both groups.

The new guidance is the first update since 2008, replacing the previous risk-based recommendations.

There were increases in fibrosis stage for 24% of patients in the rifaximin-α group, compared to 43% of the placebo group.

The odds of hospitalizations with acetaminophen and opioid toxicity increased by 11% per year prior to the mandate and decreased by 11% per year after the announcement.

The gene expression analysis of the liver showed mRNA levels of BCAT1, BCAT2, and BCKDA were upregulated in patients with NAFLD.

Individuals that did not respond had a lower percentage of naïve T cells compared to responders, while responders had a lower percentage of Th2 and CD4 central memory subsets before vaccination.

HCV RNA positivity was significantly more prevalent in the male patient than it was for females in both adults and the general population after excluding high-risk groups.

Acceptability of the vaccine was high among the completers and some non-completers that felt it was safe and offered them protection.

Sofosbuvir-based regimens were the most commonly prescribed therapies to treat hepatitis C virus in Asia, Africa, and the Commonwealth of Independent States.

Kim Zuber, PA-C, and Jane Davis, DNP, provide perspective on guideline recommendations for the management of hepatitis C in people with chronic kidney disease from the Kidney Disease Improving Global Outcomes.

Latino-English preferred patients had an overall lower rate of screening compared to both non-Hispanic whites and Latino-Spanish preferred patients.

Amid a blood shortage and continued stigmatization of HIV risk, it's hard to feel good about the FDA's delayed decision—though good may still come of it.

While 20% of the patient population had a Fib-4 index greater than 1.3, including 1 case of a Fib-4 index greater than 2.67, the investigators did not identify a significant increase in Fib-4 index in patients with fatty liver compared to those who did not develop fatty liver.

The majority of healthcare workers included in the study were immune to both measles and rubella.

Patients with HCC were more likely to be older, male, Asian, and have a history of hepatitis B virus.

There have been more than 12,900 studies on the involvement of dysbiosis in the gensisinfectious diseases in the last 15 years.

The number needed to screen to detect unknown anti-HCV positive individual was 262 for those unaware of their infections.

More patients are presenting with later stage liver cancer due to missed screenings during the COVID-19 pandemic.

The World Health Organization has set a goal of eradication for HCV by 2030.

The prevalence of HBV among people who inject drugs was highest in East and Southeast Asia and lowest in Western Europe.

The average hepatitis C virus incidence was 52% lower during the broad-DAA access period.

The results show significant LSM relative reductions compared to pooled placebo in aspartate aminotransferase for pegozafermin 3 mg once weekly, 27 mg once weekly, and 36 mg once every 2 weeks.

The treatment rate decreased from 64.8% to 61.2% after 2018.

Sustained virologic response was reached by 98% of the study at 12 weeks following the conclusion of treatment and remained consistent among genotype, HCV RNA values, fibrosis stage, and the subgroup of interest.

They also found a high-risk perception of HBV was associated with the willingness to be vaccinated against hepatitis B in participants from either province.

RBX2660 is the first live microbiota therapeutic approved by the FDA.

The pooled proportions of virological relapse and clinical relapse after discontinuing treatment in cirrhotic patients was 55.23 and 43.56%, respectively.

The incidence of NAFLD was 263.9 cases per 100,000 person-years in the infectious mononucleosis group, compared to 164.5 cases per 100,000 person-years in individuals without it.

HBsAg-positive women with adequate gestational weight again among pre-pregnancy normal-weight women had a higher risk of gestational diabetes mellitus than HBs-Ag-negative women.